- Home
- LAW vs CTNM Comparison
LAW vs CTNM Comparison
Compare LAW & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAW
- CTNM
- Stock Information
- Founded
- LAW 2013
- CTNM 2009
- Country
- LAW United States
- CTNM United States
- Employees
- LAW N/A
- CTNM N/A
- Industry
- LAW Computer Software: Prepackaged Software
- CTNM
- Sector
- LAW Technology
- CTNM
- Exchange
- LAW Nasdaq
- CTNM Nasdaq
- Market Cap
- LAW 249.3M
- CTNM 248.7M
- IPO Year
- LAW 2021
- CTNM 2024
- Fundamental
- Price
- LAW $6.21
- CTNM $12.16
- Analyst Decision
- LAW Buy
- CTNM Strong Buy
- Analyst Count
- LAW 2
- CTNM 5
- Target Price
- LAW $6.75
- CTNM $22.20
- AVG Volume (30 Days)
- LAW 151.3K
- CTNM 194.4K
- Earning Date
- LAW 11-05-2025
- CTNM 11-05-2025
- Dividend Yield
- LAW N/A
- CTNM N/A
- EPS Growth
- LAW N/A
- CTNM N/A
- EPS
- LAW N/A
- CTNM N/A
- Revenue
- LAW $148,024,000.00
- CTNM N/A
- Revenue This Year
- LAW $7.13
- CTNM N/A
- Revenue Next Year
- LAW $6.25
- CTNM N/A
- P/E Ratio
- LAW N/A
- CTNM N/A
- Revenue Growth
- LAW 4.05
- CTNM N/A
- 52 Week Low
- LAW $3.31
- CTNM $3.35
- 52 Week High
- LAW $6.81
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- LAW 51.09
- CTNM 56.27
- Support Level
- LAW $5.90
- CTNM $10.65
- Resistance Level
- LAW $6.54
- CTNM $12.14
- Average True Range (ATR)
- LAW 0.25
- CTNM 0.92
- MACD
- LAW -0.11
- CTNM -0.21
- Stochastic Oscillator
- LAW 8.24
- CTNM 34.98
About LAW CS Disco Inc.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.